Price of EpiPens reduced by eight percent

By Admin
Meda Pharmaceuticals is reducing the price of its EpiPen Auto-Injector by over eight percent and is also launching training devices to help patients to...

Meda Pharmaceuticals is reducing the price of its EpiPen Auto-Injector by over eight percent and is also launching training devices to help patients to use EpiPens properly.

The EpiPen Auto-Injector is the market leader for the emergency treatment of severe allergic reactions (anaphylaxis) in both children and adults.

It is thought that approximately 210,000 people in the UK are at risk of anaphylaxis and rely on the life-saving treatment, which is now priced at £26.45.

READ MORE FROM THE WDM CONTENT NETWORK:
To read the latest edition of Exec Digital, click here
Ryan Reynolds joins milk campaign

Happiness gene is revealed

Asthma pills as effective as inhalers


In addition to making the product more affordable, Meda is also offering free training devices, so patients will be able to practice using an EpiPen Auto Injector without its needle to help improve their self-administration techniques.

The EpiPens have been designed for use in stressful conditions and can be used by patients and caregivers often without the assistance of a healthcare professional.

Patients will also be able to register for expiry alerts from the EpiPen website to make sure their devices are within their expiry date.

Meda Pharmaceuticals have the exclusive marketing and distribution rights for the EpiPen Auto Injector, after signing a long-term agreement with Mylan Inc’s Dey Pharma.

David Bennett, General Manager, Meda UK said: “We are working very closely with the manufacturer to deliver a robust and consistent supply of EpiPen Auto-Injector which will continue to be available through Alliance Healthcare.”

He added: “Meda has long-standing expertise in allergy medicine throughout the world and we are keen to provide support to the prescriber, caregiver and patient alike.”

Anaphylaxis can be trigged by a number of allergies and its symptoms develop rapidly. Typical symptoms include swelling, breathing problems, an increased heart rate and a loss of consciousness.

The adrenaline chemical that is contained in the EpiPens works to combat these symptoms by reducing swelling and increasing blood pressure.
 

Share
Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI